Femoropopliteal disease refers to peripheral arterial disease (PAD) that specifically involves the superficial femoral artery (SFA) and the popliteal artery, the major vessels that run through the thigh and behind the knee to supply blood to the lower leg. Because this arterial segment is long, mobile with joint movement, and subject to repetitive mechanical stress, it is one of the most commonly affected regions in PAD and presents distinct treatment considerations.
Why Is the Femoropopliteal Segment Commonly Affected?
The femoropopliteal segment is particularly susceptible to atherosclerotic narrowing for several reasons. It is a long arterial run, which means disease can develop across an extended length rather than a short focal point. The artery also crosses the hip and knee joints, subjecting it to bending, compression, and torsional forces during daily movement — factors that can influence how well certain devices perform in this location over time.
What Symptoms Are Associated With Femoropopliteal Disease?
Narrowing in the femoropopliteal segment commonly produces classic intermittent claudication, typically felt as cramping or fatigue in the calf muscle during walking that resolves with rest. As disease progresses, some patients may experience symptoms at rest or non-healing wounds, which can indicate more advanced disease requiring prompt evaluation.
How Is Femoropopliteal Disease Diagnosed?
Diagnosis typically follows the standard PAD diagnostic pathway, including:
- Clinical history and pulse examination
- Ankle-brachial index (ABI) testing
- Duplex ultrasound to visualize blood flow and identify areas of narrowing
- CT angiography or catheter-based angiography for detailed anatomical mapping when intervention is being considered
Physicians pay particular attention to lesion length, degree of calcification, and involvement of the knee joint when planning treatment for this segment.
What Treatment Options Are Available?
Management of femoropopliteal disease depends on symptom severity, lesion characteristics, and overall patient health. Options a physician may consider include:
- Supervised exercise therapy and risk factor management for mild to moderate claudication
- Balloon angioplasty (PTA), sometimes combined with a drug-coated balloon, to open the narrowed segment
- Atherectomy to remove plaque in heavily calcified lesions before or alongside angioplasty
- Self-expanding nitinol stents, chosen in part for their flexibility across a joint-crossing segment
- Surgical bypass in select cases where endovascular approaches are not suitable
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Why Does Device Selection Matter in This Segment?
Because the femoropopliteal segment moves with the hip and knee, devices used here are often designed with flexibility and durability in mind to accommodate repetitive bending. This is a key reason nitinol — a flexible, self-expanding alloy — is frequently used in stents intended for this anatomical location, rather than more rigid balloon-expandable designs typically reserved for other vessels.
Frequently Asked Questions
Is femoropopliteal disease more serious than other forms of PAD?
Severity depends on the extent of narrowing and associated symptoms rather than the anatomical location alone. However, because this segment is a common site of PAD and affects walking capacity significantly, it is frequently the focus of clinical evaluation and treatment planning.
Can femoropopliteal disease affect both legs?
Yes, atherosclerosis can affect arteries on both sides of the body, and some patients have bilateral femoropopliteal involvement. A physician will evaluate both legs during assessment even if symptoms are more prominent on one side.
What determines whether a stent is used in this segment?
The decision to use a stent, and which type, depends on factors such as lesion length, degree of calcification, angioplasty result, and vessel anatomy. This determination is made by the treating physician based on individual imaging and procedural findings.
Related INVAMED Resources
- Atlas Peripheral Stent System
- Peripheral Arterial Disease (PAD) Products
- Contact INVAMED for More Information
Medical Disclaimer: This article is provided for general informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It is not a substitute for consultation with a qualified healthcare professional. Product indications, availability, and regulatory status vary by country. Always refer to the official Instructions for Use (IFU) and consult a licensed physician for guidance specific to your situation. INVAMED devices are intended for use by trained healthcare professionals.